

PATENT

Attorney Docket No.: UCSD1630-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Fenical et al. Art Unit: 1651
Application No.: 09/991,518 Examiner: I. Marx
Filing Date: November 16, 2001 Confirmation No.: 7755
USPTO Customer No. 28213
Title: MARINE ACTINOMYCETE TAXON FOR DRUG AND
FERMENTATION PRODUCT DISCOVERY

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies of Items B through P are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

Items A, B, C, E and H through K of information in the information disclosure statement were cited in a communication from a foreign patent office in a counterpart foreign application.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, 5/20/05, in an envelope addressed to: Mail Stop AF; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Stephanie Sharrett (Name of Person Mailing Paper)	
 (Signature)	5/20/05 (Date)

In re Application of:

Fenical, et al.

Application No.: 09/991,518

Filed: November 16, 2001


Page 2

PATENT

Attorney Docket No.: UCSD1630-1

Applicants do not believe any additional fees are due however, if any other fees are required, authorization is hereby given to charge any fees associated with the filings submitted herewith, or credit any overpayment to Deposit Account No. 07-1896. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Lisa A. Haile, J.D., Ph.D.

Reg. No.: 38,347


Telephone: (858) 677-1456

Facsimile: (858) 677-1465

Date: May 20, 2005

USPTO CUSTOMER NUMBER 28213
DLA PIPER RUDNICK GRAY CARY LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1630-1	Application No.: 09/991,518
	Applicants: Fenical, et al.	Confirmation No.: 7755
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 16, 2001	Group Art Unit: 1651



U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	A	2001/002391	5/31/01	Brandt, et al.			
	B	2001/051654	12/13/01	Elliott, et al.			
	C	2004/0138196	7/15/04	Fenical, et al.	514	192	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	D	WO96/32105	10/17/96	PCT			
	E	WO00/23614	4/27/00	PCT			
	F	WO/02/47610	6/20/02	PCT			
	G	WO/2004/071382	8/26/04	PCT			
	H	WO/2005003137	1/31/05	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	I	Beers, et al., "The Merck Manual of Diagnosis & Therapy" Seventeenth Edition, Merck Research Lab. Pages 1157, col. 2, page 1158 col. 2, page 1241, col. 2, page 1252, col. 1, Whitehouse Station NJ (1999)
	J	Crane, et al., "A Novel Enantioselective Synthetic Route to Omuralide Analogues with te Potential for Species Selectivity in Proteasome Inhibition", Organic Letters 3(9):1395-1397 (2001)
	K	DeLong, et. al., "Environmental Diversity of Bacteria and Archaea", <i>Syst. Biol.</i> 50(4):470-478, (2001)
	L	Elliott, et al., "The proteasome: A new Target for Novel Drug Therapies", Am. J. of Clin Pathology. 116(5):637-646 (2001).
	M	Feling, et al., "Salinospormide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, A Marine Bacterium of the New Genus Salinosporea" <i>Angewandte Chemie</i> (Intl. ed. In English)

EXAMINER GT\6442311.1 328342-202	DATE CONSIDERED
---	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1630-1	Application No.: 09/991,518
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicants: Fenical, et al.	Confirmation No.: 7755
	Filing Date: November 16, 2001	Group Art Unit: 1651



N	Fenical, et al., "Marine Microorganisms as a Developing Resource for Drug Discovery", <i>Pharmaceutical News</i> , 9/6, 489-494 (2002).
O	Gantt, et al., "proteasome Inhibitors Block Development of Plasmodium Spp", <i>Antimicrobial Agents and Chemotherapy</i> 42(10):2731-2738 (1998).
P	Giovannoni, Steven, "Oceans of Bacteria", <i>Nature</i> 430:515-516, (July 29, 2004).
Q	Goldberg, et al., "Not Just Research Tools-proteasome Inhibitors Offer Therapeutic Promise", <i>Nature Medicine</i> , 8(4):338-340 (2002).
R	Newton, "Il Fondo Agli Oceani Potenti Antibiotici e Anticancro" XP002304843 Abstract-English
S	Nicholas, B.J.R., "Symbiotic Approach to Drug Design" <i>Decision in Drug Design</i> , 173-186 (1983).
T	Rajender, et al., "A Simple Stereocontrolled Synthesis of Salinospramide A" <i>J. Am. Chem Soc.</i> 126(20):6230 (April 2004).
U	Rappe, et al., "Cultivation of the Ubiquitous SAR11 Marine Bacterioplankton Clade," <i>Nature</i> 418:630-633, (August 8, 2002).
V	Stackebrandt, et al., "Proposal for a New Hierarchic Classification System," <i>Intl. J. of Systematic Bacteriology</i> 47(2):479-490 (1997).
W	Tang, et al., "Proteasome Activity is Required for Anthrax Lethal Toxin to Kill Macrophages", <i>Infection & Immunity</i> 67(6):3055-3060 (June 1999)
X	Ward, Bess, "How Many Species of Prokaryotes Are There?" <i>PNAS</i> 99(16):10234-10236 (August 6, 2002).
Y	Wheelis, et al., "On the Nature of Global Classification", <i>PNAS</i> 89:2930-2934, (April 1992).
Z	Woese, Carl, "Bacterial Evolution", <i>Microbiological Rev.</i> 51(2):221-271 (June 1987)

EXAMINER GT\6442311.1 328342-202	DATE CONSIDERED
---	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.